Siegner, Sebastian M.
Ugalde, Laura
Clemens, Alexandra
Garcia-Garcia, Laura
Bueren, Juan A. http://orcid.org/0000-0002-3228-7013
Rio, Paula http://orcid.org/0000-0002-5424-5543
Karasu, Mehmet E.
Corn, Jacob E. http://orcid.org/0000-0002-7798-5309
Funding for this research was provided by:
Fanconi Anemia Research Fund (none)
EC | Horizon 2020 Framework Programme (825575)
Article History
Received: 8 April 2022
Accepted: 26 October 2022
First Online: 12 November 2022
Competing interests
: J.E.C. is a cofounder and board member of Spotlight Therapeutics, an SAB member of Mission Therapeutics, an SAB member of Relation Therapeutics, an SAB member of Hornet Bio, an SAB member for the Joint AstraZeneca-CRUK Functional Genomics Centre, and a consultant for Cimeo Therapeutics. P.R. and J.A.B receive funding and has licensed the PGK-FANCA-WPRE* lentiviral vector to Rocket Pharmaceuticals. P.R. and J.A.B. are inventors on patents filed by CIEMAT, CIBERER, and Fundación Jiménez Díaz, and may be entitled to receive financial benefits from the licensing of such patents. The rest of the authors declare that they have no competing interests.